The Filings Report

CME Group

CMENasdaqCIK 1156375Financial / Capital Marketsfiscal year ends December74 quarters since 2008

Revenue, Q3 FY2026
$1.7B
+13.0% on Q3 FY2025
Net income
$1.0B
+14.2% on Q3 FY2025
Free cash flow
$1.1B
+12.7% on Q3 FY2025
Diluted EPS
$2.89
+16.1% on Q3 FY2025
Revenue, TTM
$7.0B
trailing four quarters
Net margin, TTM
—
net income —
Free cash flow, TTM
$4.3B
$4.4B less $94M capex
Cash and equivalents
$2.2B
long-term debt —, Sep 30, 2026
Shares, 12-month change
—
— shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
$4.1B
no yield
Market value
—
at the close, buybacks

Latest quarter Q3 FY2026, filed October 23, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, CME Group reported revenue of $1.7B, +13.0% on Q3 FY2025, and net income of $1.0B (+14.2%). Operating margin was 65.7%. Free cash flow, operating cash flow less capital expenditures, was $1.1B ($1.1B less $16M). Diluted earnings per share were $2.89.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 23, 2026.

Revenue and net incomeRevenueNet income
$0$500M$1.0B$1.5B$2.0BQ4'22, Revenue: $1.2BQ4'22, Net income: $638MQ4'22Q1'23, Revenue: $1.4BQ1'23Q2'23, Revenue: $1.4BQ2'23Q3'23, Revenue: $1.3BQ3'23Q4'23, Revenue: $1.4BQ4'23Q1'24, Revenue: $1.5BQ1'24Q2'24, Revenue: $1.5BQ2'24Q3'24, Revenue: $1.6BQ3'24Q4'24, Revenue: $1.5BQ4'24Q1'25, Revenue: $1.6BQ1'25Q2'25, Revenue: $1.7BQ2'25, Net income: $1.0BQ2'25Q3'25, Revenue: $1.5BQ3'25, Net income: $908MQ3'25Q4'25, Revenue: $1.6BQ4'25, Net income: $1.2BQ4'25Q1'26, Revenue: $1.9BQ1'26Q2'26, Revenue: $1.7BQ2'26, Net income: $1.0BQ2'26Q3'26, Revenue: $1.7BQ3'26, Net income: $1.0BQ3'26$0$500M$1.0B$1.5B$2.0BQ4'22, Revenue: $1.2BQ4'22, Net income: $638MQ1'23, Revenue: $1.4BQ1'23Q2'23, Revenue: $1.4BQ3'23, Revenue: $1.3BQ3'23Q4'23, Revenue: $1.4BQ1'24, Revenue: $1.5BQ1'24Q2'24, Revenue: $1.5BQ3'24, Revenue: $1.6BQ3'24Q4'24, Revenue: $1.5BQ1'25, Revenue: $1.6BQ1'25Q2'25, Revenue: $1.7BQ2'25, Net income: $1.0BQ3'25, Revenue: $1.5BQ3'25, Net income: $908MQ3'25Q4'25, Revenue: $1.6BQ4'25, Net income: $1.2BQ1'26, Revenue: $1.9BQ1'26Q2'26, Revenue: $1.7BQ2'26, Net income: $1.0BQ3'26, Revenue: $1.7BQ3'26, Net income: $1.0BQ3'26

Net income losses drawn in red.

Free cash flow
$0$500M$1.0B$1.5BQ4'22, Free cash flow: $957MQ4'22Q1'23, Free cash flow: $887MQ1'23Q2'23, Free cash flow: $630MQ2'23Q3'23, Free cash flow: $837MQ3'23Q4'23, Free cash flow: $1.0BQ4'23Q1'24, Free cash flow: $873MQ1'24Q2'24, Free cash flow: $759MQ2'24Q3'24, Free cash flow: $973MQ3'24Q4'24, Free cash flow: $992MQ4'24Q1'25, Free cash flow: $1.1BQ1'25Q2'25, Free cash flow: $1.0BQ2'25Q3'25, Free cash flow: $950MQ3'25Q4'25, Free cash flow: $1.1BQ4'25Q1'26, Free cash flow: $1.2BQ1'26Q2'26, Free cash flow: $924MQ2'26Q3'26, Free cash flow: $1.1BQ3'26$0$500M$1.0B$1.5BQ4'22, Free cash flow: $957MQ1'23, Free cash flow: $887MQ1'23Q2'23, Free cash flow: $630MQ3'23, Free cash flow: $837MQ3'23Q4'23, Free cash flow: $1.0BQ1'24, Free cash flow: $873MQ1'24Q2'24, Free cash flow: $759MQ3'24, Free cash flow: $973MQ3'24Q4'24, Free cash flow: $992MQ1'25, Free cash flow: $1.1BQ1'25Q2'25, Free cash flow: $1.0BQ3'25, Free cash flow: $950MQ3'25Q4'25, Free cash flow: $1.1BQ1'26, Free cash flow: $1.2BQ1'26Q2'26, Free cash flow: $924MQ3'26, Free cash flow: $1.1BQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$2B$4B$6BQ4'22, Cash and equivalents: $2.7BQ4'22Q1'23, Cash and equivalents: $1.6BQ1'23Q2'23, Cash and equivalents: $1.9BQ2'23Q3'23, Cash and equivalents: $2.3BQ3'23Q4'23, Cash and equivalents: $2.9BQ4'23Q1'24, Cash and equivalents: $1.4BQ1'24Q2'24, Cash and equivalents: $1.8BQ2'24Q3'24, Cash and equivalents: $2.3BQ3'24Q4'24, Cash and equivalents: $2.9BQ4'24Q1'25, Cash and equivalents: $1.4BQ1'25Q2'25, Cash and equivalents: $2.0BQ2'25Q3'25, Cash and equivalents: $2.4BQ3'25Q4'25, Cash and equivalents: $4.4BQ4'25Q1'26, Cash and equivalents: $2.4BQ1'26Q2'26, Cash and equivalents: $2.1BQ2'26Q3'26, Cash and equivalents: $2.2BQ3'26$0$2B$4B$6BQ4'22, Cash and equivalents: $2.7BQ1'23, Cash and equivalents: $1.6BQ1'23Q2'23, Cash and equivalents: $1.9BQ3'23, Cash and equivalents: $2.3BQ3'23Q4'23, Cash and equivalents: $2.9BQ1'24, Cash and equivalents: $1.4BQ1'24Q2'24, Cash and equivalents: $1.8BQ3'24, Cash and equivalents: $2.3BQ3'24Q4'24, Cash and equivalents: $2.9BQ1'25, Cash and equivalents: $1.4BQ1'25Q2'25, Cash and equivalents: $2.0BQ3'25, Cash and equivalents: $2.4BQ3'25Q4'25, Cash and equivalents: $4.4BQ1'26, Cash and equivalents: $2.4BQ1'26Q2'26, Cash and equivalents: $2.1BQ3'26, Cash and equivalents: $2.2BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 23, 2026.

CME Group income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 23, 2026Q2 FY2026ended Jun 30, 2026filed Jul 24, 2026Q1 FY2026ended Mar 31, 2026filed Apr 24, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Oct 24, 2025Q2 FY2025ended Jun 30, 2025filed Jul 25, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 27, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue1,7371,7061,8801,6491,5381,6921,6421,525+13.0%
Cost of revenue—————————
Gross profit—————————
Research and development—————————
Selling, general and administrative—————————
Operating income1,1411,1071,3101,0209731,1291,108947+17.4%
Other income (expense)213221201559204201137150+4.4%
Pretax income1,3551,3281,5111,5781,1771,3301,2451,097+15.1%
Income tax318286357396269305289222+18.2%
Net income1,0371,042—1,1839081,025——+14.2%
Diluted EPS ($)2.892.883.18—2.492.812.62—+16.1%
Diluted shares (millions)359361363—360360360——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 23, 2026.

CME Group balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 23, 2026Q2 FY2026ended Jun 30, 2026filed Jul 24, 2026Q1 FY2026ended Mar 31, 2026filed Apr 24, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Oct 24, 2025Q2 FY2025ended Jun 30, 2025filed Jul 25, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 27, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents2,1992,1442,3914,4172,4471,9811,4052,892−10.1%
Short-term investments131131124125123118114113+6.3%
Total current assets159,138161,631169,001165,359152,801145,450123,445103,034+4.1%
Total assets192,093194,677201,994198,424187,145179,907157,832137,447+2.6%
Total current liabilities156,113158,717165,998160,297149,587142,795121,420102,314+4.4%
Long-term debt—————————
Total liabilities165,532168,156175,375169,696158,954152,168130,801110,960+4.1%
Stockholders’ equity26,56026,52026,61828,72828,19027,73927,03126,487−5.8%
Shares outstanding (millions)—————————

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 23, 2026.

CME Group cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 23, 2026Q2 FY2026ended Jun 30, 2026filed Jul 24, 2026Q1 FY2026ended Mar 31, 2026filed Apr 24, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Oct 24, 2025Q2 FY2025ended Jun 30, 2025filed Jul 25, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 27, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow1,0869471,2601,1349681,0591,1171,018+12.2%
Capital expenditures1624223318181426−14.1%
Free cash flow (CFO − capex)1,0709241,2381,1019501,0401,102992+12.7%
Depreciation and amortization—————————
Share repurchases—————————
Dividends paid4654682,6984554554552,567419+2.1%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 26, 2026.

Income statement

CME Group income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 27, 2025FY2023ended Dec 31, 2023filed Feb 28, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 26, 2021FY2019ended Dec 31, 2019filed Feb 28, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Mar 1, 2018FY2016ended Dec 31, 2016filed Feb 27, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 26, 2015FY2013ended Dec 31, 2013filed Mar 3, 2014FY2012ended Dec 31, 2012filed Mar 1, 2013FY2011ended Dec 31, 2011filed Feb 28, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Feb 26, 2010FY2008ended Dec 31, 2008filed Sep 4, 2009FY2007ended Dec 31, 2007filed Sep 4, 2009
Revenue6,5216,1305,5795,0194,6904,8844,8684,3093,6453,5953,3273,1132,9362,9153,2813,0042,6132,5611,756
Cost of revenue———————————————————
Gross profit———————————————————
Research and development———————————————————
Selling, general and administrative———————————————————
Operating income4,2303,9323,4363,0162,6452,6372,5882,6082,3112,2011,9891,7681,6371,6922,0211,8311,5891,5821,052
Other income (expense)1,1016107184747288510217021687(32)3(36)1(85)(109)(152)(334)44
Pretax income5,3314,5414,1543,4903,3742,7222,6902,7782,5262,2881,9571,7711,6011,6931,9371,7221,4381,248—
Income tax1,2581,016927799737616574814(1,537)754710645623787122770612533437
Net income4,0723,5263,2262,6912,6372,1062,1171,9624,0631,5341,2471,1279778961,812951826716659
Diluted EPS ($)11.169.678.867.407.295.875.915.7111.944.533.693.352.922.705.432.862.48*2.43*2.99*
Diluted shares (millions)360360360359359359358344340339338336334332334332333*295*221*

Balance sheet

CME Group balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 27, 2025FY2023ended Dec 31, 2023filed Feb 28, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 26, 2021FY2019ended Dec 31, 2019filed Feb 28, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Mar 1, 2018FY2016ended Dec 31, 2016filed Feb 27, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 26, 2015FY2013ended Dec 31, 2013filed Mar 3, 2014FY2012ended Dec 31, 2012filed Mar 1, 2013FY2011ended Dec 31, 2011filed Feb 28, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Feb 26, 2010FY2008ended Dec 31, 2008filed Sep 4, 2009FY2007ended Dec 31, 2007filed Sep 4, 2009
Cash and equivalents4,4172,8922,9122,7202,8351,6331,5511,3751,9041,8691,6931,3662,4701,6051,042855261298845
Short-term investments125113112961151018373908373756857485043310—
Total current assets165,359103,03494,890139,078161,76289,28439,56841,88746,90740,03237,90542,54524,4068,71810,9465,3886,69919,112—
Total assets198,424137,447129,706174,176196,780124,66075,21577,47675,79169,36967,35972,24254,27838,86340,75935,04635,65148,159—
Total current liabilities160,297102,31493,417137,688160,39888,19838,52341,27345,67338,94636,82541,53123,3117,6179,6154,7816,52418,643—
Long-term debt———————————————————
Total liabilities169,696110,960102,968147,297169,38198,30849,05651,51053,37949,02946,80851,31833,11717,35819,13614,91816,35029,470—
Stockholders’ equity28,72826,48726,73826,87927,39926,35226,15925,96522,41220,34120,55220,92421,15521,41921,55220,06019,30118,68912,306
Shares outstanding (millions)————————————————333*——

Cash flow statement

CME Group cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 27, 2025FY2023ended Dec 31, 2023filed Feb 28, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 26, 2021FY2019ended Dec 31, 2019filed Feb 28, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Mar 1, 2018FY2016ended Dec 31, 2016filed Feb 27, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 26, 2015FY2013ended Dec 31, 2013filed Mar 3, 2014FY2012ended Dec 31, 2012filed Mar 1, 2013FY2011ended Dec 31, 2011filed Feb 28, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Feb 26, 2010FY2008ended Dec 31, 2008filed Sep 4, 2009FY2007ended Dec 31, 2007filed Sep 4, 2009
Operating cash flow4,2773,6913,4543,0562,4022,7162,6732,4411,7511,7321,5331,2911,2811,2201,3461,3601,0831,197814
Capital expenditures849476901271982461178292114141126142172160158200164
Free cash flow (CFO − capex)4,1943,5973,3772,9662,2752,5182,4272,3241,6691,6401,4181,1511,1551,0781,1741,200925997651
Depreciation and amortization108115126135148153159119113129129133135137129130126137106
Share repurchases————————————0022057527224949
Dividends paid3,9333,5843,2362,6342,1892,1101,6962,1501,9941,7871,3431,4975991,224373305306615152

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$79K
1 purchases by 1 insider; officers and directors $79K
Sold, three months
$6M
5 sales by 4 insiders; officers and directors $6M
Bought, twelve months
$667K
7 purchases by 1 insider; officers and directors $667K
Sold, twelve months
$33M
20 sales by 11 insiders; officers and directors $33M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 27, 2026Cutinho SunilChief Information Officeropen-market sale5,000$298.70$1M20,037Oct 27, 2026
Oct 22, 2026Gepsman Martin JDirectoropen-market sale400$302.50$121K25,244Oct 22, 2026
Sep 25, 2026Shepard William RDirectoropen-market buyindirect293$268.76$79K263,289Sep 28, 2026
Sep 16, 2026Winkler JulieSr MD Chief Commercial Officertax withholding359$272.46$98K31,561Sep 17, 2026
Sep 16, 2026Vroman KenChief Transformation Officertax withholding308$272.46$84K20,232Sep 17, 2026
Sep 16, 2026Tobin Jack JMD Chief Accounting Officertax withholding51$272.46$14K25,762Sep 17, 2026
Sep 16, 2026Sprague SuzanneCOO & Global Head of Clearingtax withholding308$272.46$84K15,548Sep 17, 2026
Sep 16, 2026Sammann DerekSr MD Gl Hd Commodities Mktstax withholding359$272.46$98K10,134Sep 17, 2026
Sep 16, 2026McCourt Timothy FrancisSr MD Global Head Equity & FXtax withholding364$272.46$99K13,366Sep 17, 2026
Sep 16, 2026Marchese John CliffordSr MD, General Counseltax withholding44$272.46$12K3,598Sep 17, 2026
Sep 16, 2026Fitzpatrick LynnePresident and CFOtax withholding359$272.46$98K26,661Sep 17, 2026
Sep 16, 2026Dennis Michael G.Global Head of Fixed Incometax withholding274$272.46$75K10,682Sep 17, 2026
Sep 16, 2026Cutinho SunilChief Information Officertax withholding359$272.46$98K25,037Sep 17, 2026
Sep 15, 2026Winkler JulieSr MD Chief Commercial Officeraward2,864$275.09$788K32,974Sep 17, 2026
Sep 15, 2026Winkler JulieSr MD Chief Commercial Officertax withholding373$275.09$103K32,601Sep 17, 2026
Sep 15, 2026Winkler JulieSr MD Chief Commercial Officertax withholding361$275.09$99K32,240Sep 17, 2026
Sep 15, 2026Winkler JulieSr MD Chief Commercial Officertax withholding320$275.09$88K31,920Sep 17, 2026
Sep 15, 2026Vroman KenChief Transformation Officeraward2,592$275.09$713K21,443Sep 17, 2026
Sep 15, 2026Vroman KenChief Transformation Officertax withholding320$275.09$88K21,123Sep 17, 2026
Sep 15, 2026Vroman KenChief Transformation Officertax withholding309$275.09$85K20,814Sep 17, 2026
Sep 15, 2026Vroman KenChief Transformation Officertax withholding274$275.09$75K20,540Sep 17, 2026
Sep 15, 2026Tobin Jack JMD Chief Accounting Officeraward700$275.09$193K26,109Sep 17, 2026
Sep 15, 2026Tobin Jack JMD Chief Accounting Officertax withholding44$275.09$12K26,065Sep 17, 2026
Sep 15, 2026Tobin Jack JMD Chief Accounting Officertax withholding47$275.09$13K26,018Sep 17, 2026
Sep 15, 2026Tobin Jack JMD Chief Accounting Officertax withholding205$275.09$56K25,813Sep 17, 2026

Full insider history for CME Group, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

2 of the tracked managers held CME in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded CME by quarter.

FundManagerQuarterValueSharesWeightMove
Baupost GroupSeth KlarmanQ2 2026$137M619,0002.52%new
Baron Capital GroupRon BaronQ2 2026$11M50,2340.02%trimmed −2.8%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
CME GROUP INC., CIK 1156375 on EDGAR
Extract generated
October 26, 2026
Withheld
none
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: income tax FY2011
XBRL concepts behind each line

Income statement

Revenue: Revenues
Cost of revenue: not filed
Gross profit: not filed
Research and development: not filed
Selling, general and administrative: not filed
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: MarketableSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: not filed
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated October 26, 2026.

JSON file
/data/financials/CME.json